A Phase III, Multicentre, Randomised, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Tozorakimab (MEDI3506) in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen
Latest Information Update: 26 Apr 2025
At a glance
- Drugs Tozorakimab (Primary)
- Indications Lung disorders; Viral infections
- Focus Registrational; Therapeutic Use
- Acronyms TILIA
- Sponsors AstraZeneca; AstraZeneca AB
- 29 Jan 2025 Planned End Date changed from 17 Mar 2025 to 19 Jun 2026.
- 29 Jan 2025 Planned primary completion date changed from 17 Mar 2025 to 19 Jun 2026.
- 20 Nov 2024 Planned number of patients changed from 2902 to 2870.